Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy ProgramGlobeNewsWire • 12/17/20
Surface Oncology to Participate in the 3rd Annual Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/25/20
Surface Oncology Announces SRF617 and SRF388 Will Advance to Combination and Expansion Stages of Ongoing Phase 1 Clinical TrialsGlobeNewsWire • 11/13/20
Surface Oncology Announces FDA Fast Track Designation Granted by U.S. Food and Drug Administration for SRF388 to Treat Liver CancerGlobeNewsWire • 11/11/20
Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2020GlobeNewsWire • 11/10/20
Surface Oncology to Present SRF388 and SRF114 Preclinical Data at the Upcoming Society for Immunotherapy for Cancer 2020 Virtual ConferenceGlobeNewsWire • 11/09/20
Surface Oncology to Report SRF388 Preclinical Data at the Upcoming International Cytokine and Interferon Society's Cytokines 2020 Virtual ConferenceGlobeNewsWire • 10/26/20
Surface Oncology to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech SummitGlobeNewsWire • 09/16/20
Surface Oncology to Participate in the H.C. Wainwright Global Healthcare ConferenceGlobeNewsWire • 09/11/20
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2020GlobeNewsWire • 08/11/20
Surface Oncology to Present at the 2020 Wedbush PacGrow Healthcare Virtual ConferenceGlobeNewsWire • 08/05/20